Study of safety, tolerability, and immunogenicity of an investigational herpes zoster vaccine (Z-1018) compared to Shingrix®

The company Dynavax Technologies Corporation is commencing recruitment for the clinical trial of the Trial to Evaluate the Safety, Tolerability, and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adult Volunteers.

The conditions are Shingles, Herpes Zoster, Vaccine-Preventable Diseases.

A new clinical trial is recruiting patients in the following locations: Australia.

The trial officially began on the January 10, 2022 and is planned to complete on January 31, 2023.

This is a randomized, active-controlled, dose-escalation multi-center study of 2 doses (Day 1 and Week 8) of an investigational herpes zoster (HZ) vaccine (Z-1018), combining herpes zoster antigen- (gE) with a Toll-like receptor 9 (TLR9) agonist adjuvant (CpG 1018) with and without alum in approximately 150 healthy volunteers 50 to 69 years of age (inclusive).

The link to the complete study profile: https://ichgcp.net/clinical-trials-registry/NCT05245838.